Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about Celltrion aggregated by PharmaCompass.com.

    Client Virtual Booth

    CELLTRION

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Celltrion
    korearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    Yeonsu-gu, Incheon Metropolitan City
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.celltrion.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/celltrion/
    Twitter
    Twitter
    https://twitter.com/celltriondream?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Celltrion USA completes submission of BLA to U.S. FDA for CT-P39
    Celltrion USA completes submission of BLA to U.S. FDA for CT-P39

    https://www.prnewswire.com/news-releases/celltrion-usa-completes-submission-of-biologics-license-application-bla-to-us-fda-for-ct-p39-an-interchangeable-biosimilar-candidate-of-xolair-omalizumab-302084902.html

    PR NEWSWIRE
    10 Mar 2024
    Share Share
    Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC)
    Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC)

    https://www.businesswire.com/news/home/20240220426905/en

    BUSINESSWIRE
    23 Feb 2024
    Share Share
    Health Canada Approves Remsima™ SC for the Treatment of IBD
    Health Canada Approves Remsima™ SC for the Treatment of IBD

    https://www.businesswire.com/news/home/20240217328992/en

    BUSINESSWIRE
    18 Feb 2024
    Share Share
    Celltrion USA completes submission of Biologics License Application for CT-P47
    Celltrion USA completes submission of Biologics License Application for CT-P47

    https://www.prnewswire.com/news-releases/celltrion-usa-completes-submission-of-biologics-license-application-for-ct-p47-a-biosimilar-candidate-of-actemra-tocilizumab-302046308.html

    PR NEWSWIRE
    28 Jan 2024
    Share Share
    Newly spun-off WuXi XDC locks up ADC deal with Korea's Celltrion
    Newly spun-off WuXi XDC locks up ADC deal with Korea's Celltrion

    https://www.fiercepharma.com/pharma/wuxi-xdc-hot-520m-ipo-inks-antibody-drug-conjugate-deal-celltrion

    FIERCE PHARMA
    24 Jan 2024
    Share Share
    Celltrion's Biologic Yuflyma (adalimumab) Receives Approval in the U.S.
    Celltrion's Biologic Yuflyma (adalimumab) Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761219

    FDA
    30 Nov 2023
    Share Share
    Celltrion USA announces distribution and incorporation of YUFLYMA
    Celltrion USA announces distribution and incorporation of YUFLYMA

    https://www.businesswire.com/news/home/20231016926590/en

    BUSINESSWIRE
    26 Oct 2023
    Share Share
    Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA
    Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA

    https://www.businesswire.com/news/home/20231022057773/en/Celltrion-USA-Announces-U.S.-FDA-Approval-of-ZYMFENTRA%C2%AE-infliximab-dyyb-the-First-and-Only-Subcutaneous-infliximab-for-the-Treatment-of-People-With-Inflammatory-Bowel-Disease

    BUSINESSWIRE
    23 Oct 2023
    Share Share
    Celltrion & Celltrion Healthcare Announce Shareholders Approval of Merger
    Celltrion & Celltrion Healthcare Announce Shareholders Approval of Merger

    https://www.businesswire.com/news/home/20231022080942/en

    BUSINESSWIRE
    23 Oct 2023
    Share Share
    Celltrion's Biologic Zymfentra (infliximab) Receives Approval in the U.S.
    Celltrion's Biologic Zymfentra (infliximab) Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761358

    FDA
    20 Oct 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search